Renowned leaders Alessandra Cesano, Julie Cherrington, and Mike Varney to serve in scientific and strategic advisor roles
GV20 Therapeutics, a biopharmaceutical company using cutting-edge genomics and artificial intelligence approaches to discover next-generation cancer therapeutics, announced the appointment of three key advisers as it prepares to advance its first drug candidate into the clinic. Appointments include Alessandra Cesano, M.D., Ph.D., current Chief Medical Officer of ESSA Pharmaceuticals; Julie Cherrington, Ph.D., a drug development expert who has served as the CEO of multiple oncology companies; and Mike Varney, Ph.D., the former head of Genentech Research and Early Development (gRED).
“We are thrilled to welcome Alessandra, Julie, and Mike at this pivotal time for our company,” said Shirley Liu, CEO of GV20. “Our advisers are some of the most respected and accomplished leaders in oncology, with a wealth of experience building companies and translating innovative science into medicines for patients. Their recruitment speaks to the promise of our integrated STEAD genomics and AI platform. Their guidance will be a critical asset for us as we advance XBH25 towards the clinic and work to expand our pipeline.”
Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!